Glassock, Richard J.
Article History
First Online: 14 February 2019
Competing interests
: R.J.G is a consultant for Bristol-Myers Squibb, Chemocentryx, Apellis, Ionis, Achillion, Omeros and Mallinckrodt. He owns stock in Reata, Inc. (bardoxolone) and receives editorial stipends from Wolters-Kluwer (UpToDate) and Karger Publications (<i>American Journal of Nephrology</i> and <i>Nephrology Viewpoints</i>).